Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Tumor Growth Blocked in Mice by Suppressing Antioxidants in Cancer Cells

By BiotechDaily International staff writers
Posted on 11 Dec 2013
Many cancers have adapted to deal with the high levels of immune system-produced free radicals, also referred to as reactive oxygen species, by overproducing antioxidant proteins. One of these proteins, superoxide dismutase 1 (SOD1), is overproduced in lung adenocarcinomas and has been implicated as a target for chemotherapy.

In the December 2, 2013, issue of the Journal of Clinical Investigation, Dr. Navdeep Chandel and colleagues from Northwestern University (Evanston, IL, USA) reported the effects of a SOD1 pharmacologic suppressor on non-small-cell lung cancer (NSCLC) cells. The inhibitor, called ATN-224, blocked the growth of human NSCLC cells in culture, and triggered their death. The researchers also discovered that ATN-224 inhibited other antioxidant proteins, which caused high levels of hydrogen peroxide inside the cells. Cancer cells’ capability to generate hydrogen peroxide was required for ATN-224-dependent effects, because hydrogen peroxide activated cell death pathways.

ATN-224, moreover, triggered cancer cell death and decreased tumor sizes in a mouse model of lung adenocarcinoma. ATN-224-dependent effects in lab mice were enhanced when the inhibitor was used in combination with another drug that activates programmed cell death.

These new findings indicate that antioxidant suppression may be a feasible chemotherapeutic strategy.

Related Links:

Northwestern University



comments powered by Disqus

Channels

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.